Zhejiang Zhenyuan ademetionine succinate is expected to obtain production approval in the first half of the year
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Zhou Qianli, a secretary of the board of directors of Zhenyuan, Zhejiang Province, said at the strategic meeting of securities companies that the company's new drug for liver and gall, ademetionine succinate API and injection, is expected to obtain production approval in the first half of the year On March 20, the status of the new drug changed to "under approval", and it is expected to get the production approval document in the second quarter, when it will share the domestic market with Abbott and Haizheng pharmaceutical According to the official website of Zhenyuan Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Zhenyuan, ademetionine succinate was developed by the company in 2004 Up to now, the company has invested tens of millions of yuan in R & D and supporting production equipment system costs If it is approved for listing, it is likely to become a major new strategic product Data show that adenosylmethionine is a kind of physiologically active molecule commonly existing in human tissues and body fluids, which is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, and can make the abnormal liver function caused by various reasons turn to normal It is reported that adenosylmethionine succinate, the first pharmaceutical imitator of Haizheng pharmaceutical, achieved a revenue of more than 100 million yuan in the first half of 2013.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
